T
Tadashi Matsushita
Researcher at Nagoya University
Publications - 334
Citations - 6662
Tadashi Matsushita is an academic researcher from Nagoya University. The author has contributed to research in topics: Medicine & Haemophilia. The author has an hindex of 41, co-authored 310 publications receiving 5948 citations. Previous affiliations of Tadashi Matsushita include Washington University in St. Louis & RMIT University.
Papers
More filters
Journal ArticleDOI
Integrin activation and matrix binding mediate cellular responses to mechanical stretch.
TL;DR: It is shown that mechanical strain stimulates conformational activation of integrin αvβ3 in NIH3T3 cells, defining a molecular mechanism for the role of integrins in mechanotransduction.
Journal ArticleDOI
Complete antithrombin deficiency in mice results in embryonic lethality
Kazuhiro Ishiguro,Tetsuhito Kojima,Kenji Kadomatsu,Yukiko Nakayama,Akira Takagi,Misao Suzuki,Naoki Takeda,Masafumi Ito,Koji Yamamoto,Tadashi Matsushita,Kazuo Kusugami,Takashi Muramatsu,Hidehiko Saito +12 more
TL;DR: It is suggested that antithrombin is essential for embryonic survival and that it plays an important role in regulation of blood coagulation in the myocardium and liver.
Journal ArticleDOI
An antiangiogenic isoform of VEGF-A contributes to impaired vascularization in peripheral artery disease
Ryosuke Kikuchi,Kazuto Nakamura,Susan MacLauchlan,Doan T.M. Ngo,Ippei Shimizu,José J. Fuster,Yasufumi Katanasaka,Sumiko Yoshida,Yan Qiu,Terry P. Yamaguchi,Tadashi Matsushita,Toyoaki Murohara,Noyan Gokce,David O. Bates,Naomi M. Hamburg,Kenneth Walsh +15 more
TL;DR: Results indicate that inflammation-driven expression of the antiangiogenic VEGF-A isoform can contribute to impaired collateralization in ischemic cardiovascular disease.
Journal ArticleDOI
Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial.
Peter William Collins,Guy Young,Karin Knobe,Faraizah Abdul Karim,Pantep Angchaisuksiri,Claus Banner,Türkiz Gürsel,Johnny Mahlangu,Tadashi Matsushita,Eveline P. Mauser-Bunschoten,Johannes Oldenburg,Christopher E. Walsh,Claude Negrier +12 more
TL;DR: Nonacog beta pegol was well tolerated and efficacious for the treatment of bleeding episodes and was associated with low ABRs in patients receiving prophylaxis, and improved health-related quality of life with EuroQoL-5 Dimensions visual analog scale score.
Journal ArticleDOI
Enhancing the pharmacokinetic properties of recombinant factor VIII: first-in-human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A.
Andreas Tiede,B. Brand,Roland Fischer,Kaan Kavakli,Steven R. Lentz,Tadashi Matsushita,C. Rea,K. Knobe,Dorthe Viuff +8 more
TL;DR: N8‐GP is a recombinant factor VIII (FVIII) with a site‐directed glycoPEGylation for the purpose of half‐life prolongation.